Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References ZolgensmaⓇ grew 28% in the quarter mainly due to geographic expansion, YTD sales over a billion Sales evolution USD m, %cc Ex-US US YTD sales growth vs. PY Q3 highlights +49% 1.0bn +28% 666 375 658 291 313 249 169 353 351 122 126 Q3 2020 Q3 2021 9M 2020 9M 2021 ■ Growth driven by expanding access in EU, emerging markets ■ Steady US sales continue to be driven by incident patients ■ Access pathways in 23 countries ■ 1.6k+ patients have been treated with ZolgensmaⓇ worldwide¹ 2021 growth drivers ■ Reimbursement: Implementation of recent agreements (i.e. Russia, BeneluxA) ■ Newborn screening: ~84% in US; on track for 20% in EU end 2021 Advancing robust data in SMA ■ STEER (global Ph3 OAV101 IT in patients ages 2-18 with later- onset SMA): anticipate screening first patients by end 2021 ■ SMART (Ph3b study for Zolgensma IV in children up to 21 kg²): rapid enrollment reflects real-world interest and use BeneluxA - Belgium, Netherlands, Luxembourg, Austria 1. Commercially, via managed access programs and in clinical trials 2. SMART is enrolling children ≥ 8.5 kg and ≤ 21 kg 29 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation